Other · developed by Heron Therapeutics
HTX-009 is a combination product given by injection and instillation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02504580 | Phase 2 | Postoperative Pain | Completed | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Postoperative Pain
Updated Oct 18, 2026. Something wrong or missing? Report it on the HRTX page.
See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRTX catalysts and pipeline →